CN113637084B - 生物大分子靶向特异性补体抑制剂及其制备方法与应用 - Google Patents

生物大分子靶向特异性补体抑制剂及其制备方法与应用

Info

Publication number
CN113637084B
CN113637084B CN202010393721.9A CN202010393721A CN113637084B CN 113637084 B CN113637084 B CN 113637084B CN 202010393721 A CN202010393721 A CN 202010393721A CN 113637084 B CN113637084 B CN 113637084B
Authority
CN
China
Prior art keywords
val
pro
ser
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010393721.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113637084A (zh
Inventor
胡维国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kang Jing Bio Medical Science And Technology Co ltd
Original Assignee
Shanghai Kang Jing Bio Medical Science And Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202010393721.9A priority Critical patent/CN113637084B/zh
Application filed by Shanghai Kang Jing Bio Medical Science And Technology Co ltd filed Critical Shanghai Kang Jing Bio Medical Science And Technology Co ltd
Priority to JP2022568638A priority patent/JP7834347B2/ja
Priority to PCT/CN2021/092861 priority patent/WO2021228052A1/zh
Priority to CN202180034009.2A priority patent/CN115515985A/zh
Priority to US17/998,367 priority patent/US20230348554A1/en
Priority to EP21804660.5A priority patent/EP4151659A4/en
Priority to CA3178088A priority patent/CA3178088A1/en
Publication of CN113637084A publication Critical patent/CN113637084A/zh
Application granted granted Critical
Publication of CN113637084B publication Critical patent/CN113637084B/zh
Priority to JP2025209848A priority patent/JP2026035742A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202010393721.9A 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用 Active CN113637084B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202010393721.9A CN113637084B (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用
PCT/CN2021/092861 WO2021228052A1 (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用
CN202180034009.2A CN115515985A (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用
US17/998,367 US20230348554A1 (en) 2020-05-11 2021-05-10 Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof
JP2022568638A JP7834347B2 (ja) 2020-05-11 2021-05-10 生体高分子標的特異的補体阻害剤及びその製造方法と応用
EP21804660.5A EP4151659A4 (en) 2020-05-11 2021-05-10 TARGET-SPECIFIC BIOLOGICAL MACROMOLECULAR COMPLEMENT INHIBITOR, PREPARATION METHOD AND USE THEREOF
CA3178088A CA3178088A1 (en) 2020-05-11 2021-05-10 Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof
JP2025209848A JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010393721.9A CN113637084B (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN113637084A CN113637084A (zh) 2021-11-12
CN113637084B true CN113637084B (zh) 2025-08-01

Family

ID=78415417

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010393721.9A Active CN113637084B (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用
CN202180034009.2A Pending CN115515985A (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180034009.2A Pending CN115515985A (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Country Status (6)

Country Link
US (1) US20230348554A1 (https=)
EP (1) EP4151659A4 (https=)
JP (2) JP7834347B2 (https=)
CN (2) CN113637084B (https=)
CA (1) CA3178088A1 (https=)
WO (1) WO2021228052A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114920849A (zh) * 2022-03-09 2022-08-19 安徽省立医院(中国科学技术大学附属第一医院) 一种靶向补体免疫抑制蛋白及其构建方法及应用
WO2025103318A1 (zh) * 2023-11-13 2025-05-22 沈阳三生制药有限责任公司 一种靶向C3b的双功能融合蛋白及其制备方法与用途
CN121159642B (zh) * 2025-11-20 2026-04-03 山东第二医科大学 补体c9迷你结合蛋白或其突变体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107005A (zh) * 2004-10-12 2008-01-16 健泰科生物技术公司 用于预防和治疗补体相关紊乱的CRIg多肽
CN104231085A (zh) * 2013-09-05 2014-12-24 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
CN110317272A (zh) * 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017114401A1 (zh) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
WO2019075519A1 (en) * 2017-10-18 2019-04-25 Csl Limited HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
SI3793586T1 (sl) * 2018-05-16 2024-07-31 Csl Limited Različice receptorja za topni komplement tipa 1 in njihova uporaba
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107005A (zh) * 2004-10-12 2008-01-16 健泰科生物技术公司 用于预防和治疗补体相关紊乱的CRIg多肽
CN110317272A (zh) * 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
CN104231085A (zh) * 2013-09-05 2014-12-24 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A novel CRIg-targeted complement inhibitor protects cells from complement damage;Qian Qiao等;《The FASEB Journal》;20141130;第28卷(第11期);第4986-4999页，特别是摘要、材料与方法 *
Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily;Xiaoxu Wang等;《J Am Soc Nephrol》;20180612;第29卷(第8期);第2053-2059页，特别是摘要、方法 *

Also Published As

Publication number Publication date
CN115515985A (zh) 2022-12-23
CA3178088A1 (en) 2021-11-18
WO2021228052A1 (zh) 2021-11-18
JP7834347B2 (ja) 2026-03-24
JP2023526218A (ja) 2023-06-21
CN113637084A (zh) 2021-11-12
EP4151659A4 (en) 2024-07-24
EP4151659A1 (en) 2023-03-22
JP2026035742A (ja) 2026-03-04
US20230348554A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7657249B2 (ja) 治療用ヌクレアーゼ組成物および方法
AU2020202119B2 (en) Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions
CN110719920B (zh) 蛋白质异二聚体及其用途
AU2018211985B2 (en) Tissue-specific Wnt signal enhancing molecules and uses thereof
KR101901458B1 (ko) Ｔｃｒ 복합체 면역치료제
KR101715445B1 (ko) 면역접합체
KR101667096B1 (ko) 돌연변이 인터루킨-2 폴리펩티드
KR102376451B1 (ko) 성장 분화 인자 15(ｇｄｆ-15) 작제물
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
KR101682496B1 (ko) 혈관형성 유도인자를 길항하는 융합단백질 및 그 용도
CN107056951A (zh) Cd86拮抗物多靶点结合蛋白
KR102175878B1 (ko) Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
CN114437228B (zh) 一种il-2与抗体亚单位构成的双功能融合蛋白
CN113637084B (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
KR20220150320A (ko) Hiv 치료를 위한 림프구에서 외생성 인자의 주문형 발현
CN109536476A (zh) 具备透明质酸酶活性的靶向融合蛋白、制备方法及用途
HK40053193A (en) Biological macromolecular target-specific complement inhibitor, preparation method thereof, and application thereof
CN100515496C (zh) 免疫调节剂及其应用
KR20130110577A (ko) Ｔｎｆｒ２의 최적화 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053193

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 201315 Floor 9, Building 1, No. 430, Miaoqiao Road, Pudong New Area, Shanghai

Applicant after: Shanghai Kang Jing Bio Medical Science and Technology Co.,Ltd.

Address before: Room 1202, No. 781 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: Shanghai Kang Jing Bio Medical Science and Technology Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment